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Mitophagy is a selective form of macro-autophagy in which mitochondria are selectively targeted for degradation
in autophagolysosomes. Mitophagy can have the beneficial effect of eliminating old and/or damaged mitochondria,
thus maintaining the integrity of the mitochondrial pool. However, mitophagy is not only limited to the turnover of
dysfunctional mitochondria but also promotes reduction of overall mitochondrial mass in response to certain
stresses, such as hypoxia and nutrient starvation. This prevents generation of reactive oxygen species and conserves
valuable nutrients (such as oxygen) from being consumed inefficiently, thereby promoting cellular survival under
conditions of energetic stress. The failure to properly modulate mitochondrial turnover in response to oncogenic
stresses has been implicated both positively and negatively in tumorigenesis, while the potential of targeting
mitophagy specifically as opposed to autophagy in general as a therapeutic strategy remains to be explored. The
challenges and opportunities that come with our heightened understanding of the role of mitophagy in cancer are
reviewed here.
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Macro-autophagy (henceforth referred to as autophagy)
is a highly conserved self-degradative process by which
cytosolic constituents, including organelles, protein ag-
gregates, and pathogens are captured by nascent phago-
phore membranes and degraded through fusion of the
resulting autophagosomes with lysosomes [1,2]. As such,
autophagy plays an important housekeeping function for
the cell in getting rid of large and potentially toxic struc-
tures [1,3-6]. Autophagy also plays a critical role in re-
cycling the breakdown products generated in the form
of amino acids, nucleic acids, fatty acids, and ATP that
are released by the lysosome and used in the cell to main-
tain metabolism, growth, and survival under conditions of
nutrient deprivation [7].
There are bulk degradative forms of autophagy that
are largely non-selective for cytosolic cargo, as well as
targeted autophagy that selectively engulfs and degrades
specific cargoes [8-13]. Mitophagy is a classic example of
the latter that involves the selective targeting of mito-
chondria for degradation at the autophagosome through* Correspondence: kmacleod@uchicago.edu
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unless otherwise stated.interactions of key adaptor molecules at the outer mito-
chondrial membrane (OMM) with processed LC3 (or re-
lated molecules) at the growing phagophore membrane
[8,14-16]. These adaptor molecules include BNIP3, NIX,
and FUNDC1 in addition to mitochondrial targets of E3
ubiquitin ligases functioning at the mitochondria, such
as Parkin and Mul1, as will be discussed below.
Mitophagy promotes turnover of dysfunctional mito-
chondria that would otherwise damage the cell, but how
the cell distinguishes between functional and non-
functional mitochondria is not entirely elucidated. Loss
of mitochondrial membrane potential and mitochon-
drial fragmentation precede mitophagy [17-19], suggest-
ing that this plays a role in their selective uptake by
autophagosomes. Indeed, mitochondrial depolarization
plays a direct role in activating Parkin-dependent mito-
phagy by inducing PINK1 kinase stabilization at the
OMM [20-22]. Mitochondrial membrane depolarization
also induces proteolytic cleavage and degradation of the
fusion protein Opa-1 thereby reducing the size of mito-
chondria, a consequence that is likely to favor uptake of
mitochondria by phagophore membranes while also link-
ing mitochondrial turnover to loss of function [23,24].
Conversely, mitochondrial fusion protects healthy respir-
ing mitochondria from degradation, a mechanism that is
promoted by protein kinase A (PKA)-mediated inhibitionral. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
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deprivation, for example [18,19].
The accumulation of dysfunctional mitochondria with
time contributes to the aging process likely due to accumu-
lation of reactive oxygen species (ROS)-induced mtDNA
mutations in line with the ‘free radical theory of aging’
since mouse life span can be increased and age-related
phenotypes can be ameliorated through over-expression of
mitochondrial catalase [25,26]. However, mitophagy also
plays a key role in reducing mitochondrial mass in the
acute response to certain stresses, such as hypoxia and nu-
trient deprivation [16,27-29]. This involves the turnover of
otherwise healthy mitochondria, but it is not clear to what
extent healthy mitochondria are rendered dysfunctional by
stress-induced signaling molecules and if this requires the
active involvement of some or all of these signaling mole-
cules in mitochondrial membrane depolarization and frag-
mentation of healthy mitochondria.
Dissection of the functions of some of the regulators
and molecular adaptors involved in targeting mitochon-
dria to the autophagosome has increased our understand-
ing of how mitophagy is initiated and executed. The most
extensively characterized of these mitophagy regulators
are Parkin and Pink1, as well as BNIP3 and NIX that play
distinct and non-overlapping activities to promote mito-
phagy [30-32]. While this current cast of mitophagy-
specific modulators is rather limited, it is clear that
additional players (such as Mul1 and FUNDC1) are emer-
ging and likely to be the focus of future studies. Here, we
first review current knowledge of molecular regulators of
mitophagy with recognized roles in tumorigenesis.
Parkin and PINK1
The PARK2 (Parkin) and PARK6 (PINK1) gene products
were originally identified as mutated in human Parkin-
son’s disease (PD) and subsequently shown to function
in concert to promote mitophagy, thus implicating dys-
functional mitochondria in the etiology of PD [15]. PARK2
(Parkin) maps to a common fragile site at human chromo-
some 6q25-q26 that is frequently deleted in ovarian,
breast, bladder, lung, and other cancers [33,34]. Consistent
with a tumor suppressor function for Parkin, parkin null
mice are susceptible to spontaneous liver tumors [35] that
may be linked to functions of Parkin in lipid metabolism
in the liver [36]. Parkin null mice are also sensitized to
irradiation-induced lymphomagenesis [37]. Parkin expres-
sion increased oxidative metabolism and limited the
Warburg effect downstream of the p53 tumor suppressor,
most likely by enhancing mitochondrial integrity, possibly
explaining the tumor suppressive activity of Parkin [37].
As a component of the FBX4 Cullin-ring ligase com-
plex, Parkin has also been shown to regulate levels of
Cyclin D1, Cyclin E, and CDK4 in cancers [34], suggest-
ing that in addition to its role in mitophagy, Parkin mayalso elicit its tumor suppressor functions through inhib-
ition of the cell cycle.
The localization of the Parkin E3 ubiquitin ligase to
the mitochondria is regulated by the PINK1 (PTEN-in-
duced putative kinase 1) serine/threonine kinase that
undergoes voltage-dependent import leading to proteoly-
sis at the inner mitochondrial membrane in healthy mito-
chondria but accumulates at the outer mitochondrial
membrane in response to mitochondrial depolarization
[20,21,22,38] (Figure 1). PINK1 phosphorylates Parkin dir-
ectly but mutation of all serine and threonine residues in
Parkin did not block its translocation to the mitochon-
dria [39], and recent evidence shows that PINK1 phos-
phorylation of ubiquitin on serine 65 is required to
recruit Parkin to mitochondria [39,40]. A large number
of mitochondrial proteins have been identified as Parkin
substrates at the OMM, including Vdac1, Miro, and
Mfn-2 [15,41-43], and indeed systematic identification
of all Parkin substrates indicates that the mitochondrial
proteome is markedly altered by Parkin activity [43].
Specific targets such as Mfn-2 are phosphorylated by
PINK1 at the OMM, and Mfn-2 has been shown to se-
lectively recruit Parkin to damaged mitochondria [44].
However, the wide range of mitochondrial substrates that
are ubiquitinated and then phosphorylated by PINK1 sug-
gests that Mfn-2 may be only one of many receptors for
Parkin at the mitochondria [43,39]. Furthermore, targeting
of mitochondrial substrates by Parkin is highly dynamic
[43] with the role of mitochondrial deubiquitinases such
as USP30 in antagonizing Parkin-dependent mitophagy
recently emerging [45] and suggesting that additional sig-
naling inputs modulate Parkin’s role in mitophagy in
response to stress.
Once ubiquitinated by Parkin, some of these substrates
(such as ubiquitinated Vdac1) create a docking site for
the LC3 interacting proteins p62/SQSTM1 and NBR-1
[46-48], allowing for selective Parkin-dependent degrad-
ation of mitochondria at the autophagosome (Figure 1).
Recruitment of Parkin to depolarized membranes is inhib-
ited by the anti-apoptotic Bcl-XL, Mcl-1, and Bcl-W pro-
teins in a Beclin-independent manner, although not by
Bcl-2 itself [32]. Inhibition of mitophagy by Bcl-XL, Mcl-1,
and Bcl-W involved their direct interaction with Parkin,
blocking the interaction of Parkin with PINK1 and thus
preventing the Parkin-dependent ubiquitination of mito-
chondrial targets [32]. Conversely, the pro-apoptotic BH3
proteins Puma, Noxa, Bim, and Bad, but not the non-
canonical BH3 proteins BNIP3, Nix, or Beclin1, all pro-
moted Parkin translocation to mitochondria, possibly by
reducing the interaction of Parkin with the aforemen-
tioned Bcl-2-related molecules [32].
Alternative models to explain the role of Parkin in
mitophagy have also been proposed in which Parkin acts
much more indirectly. This speculation about how Parkin
Figure 1 Parkin recruitment to depolarized mitochondria promotes their degradation by mitophagy. In polarized mitochondria, PINK1
is degraded in the mitochondrial matrix (left), but upon membrane depolarization, PINK1 is stabilized and accumulates at the OMM, where it
phosphorylates Mfn-2 and other substrates, including ubiquitin, that act as receptors for Parkin. Once Parkin is recruited to the OMM, it ubiquitinates
key protein substrates including VDAC1 and Mfn-2, and other possibly unknown targets (substrate X). Parkin-dependent ubiquitination of
VDAC1 and other mitochondrial proteins promotes interaction with p62/Sqstm1 that in turn facilitates interaction with LC3 at nascent
phagophores thereby targeting depolarized mitochondria for degradation by autophagy.
Chourasia et al. Cancer & Metabolism  (2015) 3:4 Page 3 of 11promotes mitophagy has arisen due to the growing ap-
preciation that no single Parkin substrate is essential for
mitophagy [49] and that several Parkin substrates are
degraded by the ubiquitin-proteasome system inde-
pendent of autophagy [42]. One particularly intriguing
alternative explanation for the function of Parkin in
mitophagy emerges from evidence that targeted protea-
somal degradation of Parkin substrates imbalances the
ratio of mitochondrial to nuclear encoded proteins at
the mitochondria, resulting in the mitochondrial unfolded
protein response (UPRmt) [50]. The UPRmt renders mito-
chondria dysfunctional and activates stress signaling that
can result in mitophagy [16]. Alternatively, Parkin may
promote mitophagy indirectly by inhibiting fusion (as a
result of Mfn-1/Mfn-2 degradation) or by promoting deg-
radation of an unknown mitophagy inhibitor at the mito-
chondria [15,42].
Regulation of mitochondrial transport along microtu-
bules (MTs) is another key consequence of Parkin recruit-
ment to mitochondria [22,49]. This is achieved through
Parkin-mediated turnover of Miro, a protein that tethers
MT-associated kinesin motor protein complexes to the
OMM [41] and through Parkin-dependent recruitment of
HDAC6 (a ubiquitin-binding protein deacetylase) that also
promotes trafficking of mitochondria along MTs [46,51].
Clearly, regulation of mitochondrial trafficking by both
Miro and HDAC6 is likely to be important for successful
targeting of mitochondria to autophagosomes but again
points to a more complex role for Parkin in mitophagy
than was initially envisioned. Finally, Parkin has non-
mitochondrial substrates that influence mitochondrial
mass in cells, such as the PARIS transcriptional regula-
tor that represses PGC-1α expression to inhibit mito-
chondrial biogenesis [52].BNIP3 and NIX
Mitophagy has emerged as a key adaptive response to
hypoxia, as cells attempt to reduce their mitochondrial
mass to not only limit ROS production but also maximize
the efficient use of available oxygen [16]. Two key molecu-
lar mediators implicated in promoting hypoxia-induced
mitophagy are BNIP3 and NIX (also known as BNIP3L)
[31,48,53]. Both are target genes of the hypoxia-inducible
factors (HIFs) [54,55] although BNIP3 is more rapidly in-
duced and to higher levels than NIX as oxygen levels drop
due to the differential dependence of BNIP3 and NIX
mRNA expression on the two transactivation domains in
HIF-1α [56-58]. BNIP3 is also transcriptionally regulated
by RB/E2Fs [28], NF-κB [59], FoxO3 [60], oncogenic Ras
[61,62], and p53 [63], while NIX is regulated by p53 [64].
They both also exhibit distinct tissue-specific patterns of
expression with BNIP3 most strongly expressed in the
heart, liver, and muscle while NIX is expressed strongly
in hematopoietic tissues and testes [65,66]. Consistently,
NIX plays a key developmental role in red blood cell
maturation promoting mitochondrial clearance from
maturing reticulocytes [67,68], while BNIP3 is involved
in modulating mitochondrial integrity in the skeletal
muscle and liver [60,66].
BNIP3 and NIX integrate into the OMM as redox-
resistant homo-dimers with a short 10 to 11 amino acid
carboxy terminal tail in the intermembrane space and a
proximal 23 amino acid transmembrane domain contain-
ing a critical glycine zipper that is required for both
dimerization and membrane integration [69-71]. The
remaining amino terminal portion of both BNIP3 and
NIX protrudes out into the cytosol where both BNIP3 and
NIX interact with LC3-related molecules at associated
phagophore membranes [72,73] (Figure 2A). The direct
(A) (B)
(D)(C)
Figure 2 BNIP/NIX promotes mitophagy through direct interaction with LC3 at the phagophore. BNIP3 and NIX are both hypoxia-inducible
genes that encode molecular adaptors that promote mitophagy through interaction with processed LC3-related molecules at nascent phagophores
(A). Both BNIP3 and NIX interact with Bcl-2 and Bcl-XL through their amino terminal ends, and Bcl-2/Bcl-XL has been postulated to play both positive
and negative regulatory effects on BNIP3 function (A). BNip3 has also been shown to interact with regulators of mitochondrial fission (Drp-1)
and mitochondrial fusion (Opa-1). These interactions are positive and negative, respectively, resulting in a role for BNIP3 in promoting fission
while inhibiting fusion (B). BNIP3 has also been shown to interact with the small GTPase, Rheb, resulting in reduced Rheb activity, reduced
mTOR activity, and reduced cell growth (C). This function for BNIP3 in modulating Rheb (C) contrasts with the proposed functional interaction
of NIX with Rheb (D) that elicits a mTOR-independent effect on mitophagy by promoting LC3 processing and increased mitochondrial turnover
in cells grown on oxidative substrates (D). NIX is required for recruitment of Rheb to mitochondria and its activating effect on mitophagy.
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GABARAP is dependent on a LC3-interacting region
(LIR) located within an unstructured amino terminal re-
gion of each protein (amino acids 15 to 21 in BNIP3 and
43 to 49 in NIX) [72-74], and thus, similar to ATG32 in
yeast [75,76], BNIP3 and NIX function to target mito-
chondria directly to the autophagosome for degradation.
Binding of BNIP3 to LC3 is regulated by phosphorylation
on serine residues adjacent to the LIR motif, but the iden-
tity of the kinases responsible is not known [77]. It re-
mains to be determined to what extent other events, such
as elevated ROS, membrane depolarization, or indeed al-
tered electron flux at the respiratory chain, modulate the
BNIP3/NIX structure to induce interactions with LC3 or
other proteins involved in mitophagy.
Expression of both BNIP3 and NIX has been linked to
non-apoptotic cell death in response to various stresses,
and both proteins used to be categorized as BH3-only
proteins [31]. However, more recent work has shown
that the BH3 domain in both BNIP3 and NIX is weakly
conserved and redundant for function [78,79]. Further-
more, various normal tissues express these proteins at
high levels without inducing cell death [65,66], and thus,
additional signals that either modify or disrupt BNIP3/
NIX function are likely required for these proteins to
induce cell death [29,80]. Thus, although linked to non-
apoptotic cell death in early publications, the growingconsensus is that BNIP3 and NIX function normally as
mitochondria-specific receptors/cargo adaptors targeting
mitochondria for degradation by autophagy and that it is
disruption or inhibition of their function that leads to
non-apoptotic cell death, although key aspects of this
perspective remain to be formally tested experimentally.
Although not bona fide BH3 proteins, both BNIP3 and
NIX do interact with Bcl-2 and Bcl-XL through their
amino terminal 49 amino acids [78], the region of both
proteins that also mediates interaction with LC3-related
molecules. Thus, it has been proposed that BNIP3/NIX
interactions with Bcl-2 or Bcl-XL can modulate binding
of BNIP3/NIX to LC3 [77] (Figure 2A) although this has
not been explored in a physiological context.
BNIP3-dependent mitophagy is preceded by mitochon-
drial fragmentation and perinuclear clustering of mito-
chondria [28,81]. Over-expression of exogenous BNIP3
induces mitochondrial fragmentation possibly due to
the inhibitory interaction of BNIP3 with the fusion pro-
tein Opa-1, resulting in disruption of Opa-1 complexes
and cristae remodeling [82,83] (Figure 2B). BNIP3 also
induces translocation of the fission protein Drp-1 to
mitochondria such that over-expression of either Mfn-1
or dominant negative Drp-1 inhibited BNIP3-dependent
mitophagy [84] (Figure 2B).Thus, similar to Parkin and
other signals that promote mitophagy, there is an intim-
ate link between BNIP3 and regulators of mitochondrial
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drial dynamics in BNIP3-dependent mitophagy. Intri-
guingly, the ability of BNIP3 to promote mitochondrial
fragmentation can be uncoupled from its ability to induce
mitophagy, but again, the signals regulating the uncoup-
ling of BNIP3 functions in mitochondrial fragmentation
from its ability to promote mitophagy are not known.
Both BNIP3 and NIX also interact with Rheb, a small
GTPase that acts positively upstream of mTOR to pro-
mote cell growth [74,85]. Rheb interacts with BNIP3 in a
manner dependent on the transmembrane domain of
BNIP3 consistent with Rheb only interacting with BNIP3
dimers at the OMM [85] (Figure 2C). Similar to the bind-
ing of Bcl-2 and Bcl-XL to BNIP3 [78], Rheb binding also
required the 30 amino terminal residues of BNIP3 [85],
suggesting that Bcl-2 and Bcl-XL may modulate the
BNIP3-Rheb interaction. This work also reported that
BNIP3 repressed Rheb activity resulting in reduced
mTOR activity and slower cell growth [85], consistent
with a tumor suppressor function for BNIP3.
By contrast, the interaction of NIX with Rheb elicited
mTOR-independent effects on cell growth [74]. Rheb was
recruited to the OMM under growth conditions that stim-
ulated high levels of oxidative phosphorylation where
Rheb interacted directly with NIX and processed LC3
(Figure 2D). Over-expression of Rheb promoted LC3 pro-
cessing and increased mitophagy independent of mTOR
activity but in a NIX-dependent fashion [74]. Thus, NIX
appears to play a key role in recruiting Rheb to mitochon-
dria under conditions of high oxidative phosphorylation
leading to increased mitophagy that would be required to
maintain a healthy pool of mitochondria under high rates
of oxidative metabolism. Arguably, this more recent report
identifying positive regulation of Rheb by NIX contrasts
with the previous study in which BNIP3 repressed Rheb
activity [85]. Clearly, NIX may function differently from
BNIP3 with respect to Rheb activity in mitophagy, and
further work will be needed to reconcile these findings.
BNIP3 and NIX have both been shown to be up-
regulated in ductal carcinoma in situ (DCIS) in human
breast cancer [86,87], while loss of BNIP3 expression at
both the RNA and protein level in progression to inva-
sive ductal carcinoma of the breast was associated with
increased proliferative index and lymph node metastases
[88]. In other cancers, including hematological malignan-
cies and lung, gastric, pancreatic, and liver cancer, epigen-
etic silencing of BNIP3 expression as tumors progress to
invasiveness and metastasis has been reported [89-92]. In
pancreatic cancer in particular, inactivation of BNIP3 was
associated with chemoresistance and a poor prognosis
[89,93,94]. However, epigenetic silencing is not the
likely mechanism of BNIP3 silencing in human breast
cancer [95]. Interestingly, Tumorscape™ (Broad Institute,
Cambridge, MA, USA) showed significant deletion aroundthe BNIP3 locus at 10q26.3 in 7 out of 14 human tumor
types, including breast cancer [96] while altered sub-
cellular localization of BNIP3 in glioma, breast, and
prostate cancer has also been reported [88,97-99]. Con-
sistently, BNIP3 knockdown in the 4T07 orthotopic
mammary tumor model promoted tumor growth and
metastasis [100]. Tumor suppressor functions have also
been attributed to NIX [64] although the relative import-
ance of NIX in early-stage versus late-stage tumorigenesis
has not been dissected. Thus, similar to Parkin [37], BNIP3
and NIX both appear to play tumor suppressor roles.
Other mitophagy regulators
Mitochondrial uncoupling agents can rescue mitophagy
defects in Nix null erythroblasts [68], indicating that
alternative mitophagy mechanisms can be activated to
promote mitophagy when one particular pathway is inacti-
vated. Currently, there is no evidence to suggest that ei-
ther BNIP3 or NIX requires Parkin activity to promote
mitophagy. Conversely, while one report suggests that
BNIP3 and NIX promote Parkin recruitment to mitochon-
dria [101], another report indicates that they do not [32].
Redundancy between mechanisms of mitophagy would
explain the lack of more severe phenotypes in mice gen-
etically deleted for Parkin, BNIP3, or NIX [36,65,102].
Indeed, there are mitochondrial E3 ubiquitin ligase
complexes other than Parkin involved in regulating
mitophagy, such as Mul1, which is induced by FoxO1
and FoxO3 transcription factors in response to serum
starvation and other stresses [103]. Mul1 promotes
mitophagy in skeletal muscle, and this involves its ubi-
quitinating and targeting Mfn-2 for degradation, result-
ing in increased mitochondrial fission and mitophagy
[103]. Another novel mitophagy mechanism involves the
hypoxia-induced interaction of FUNDC1 protein at the
OMM with LC3 at the phagophore through a conserved
LIR motif in FUNDC1 [104]. Similar to the autophagy
adaptor molecule NBR1, there is a tyrosine residue rather
than the more common tryptophan at the critical +1 pos-
ition in the LIR motif of FUNDC1 [104]. Intriguingly, this
renders the FUNDC1-LC3 interaction subject to nega-
tive regulation by oncogenic SRC1 kinase activity that
phosphorylates FUNDC1 at Y18 [104,105]. Conversely,
phosphorylation of FUNDC1 by ULK-1 on serine 17, im-
mediately adjacent to Y18 in the LIR motif of FUNDC1,
promotes the interaction of FUNDC1 with LC3 and facili-
tates mitochondrial turnover [105]. ULK-1 translocation
to mitochondria was induced by hypoxia (or mitochon-
drial uncoupling agents) where it was shown to interact
directly with FUNDC1 [105]. Interestingly, FUNDC1 and
NIX are both repressed by a hypoxia-induced microRNA,
miR-137, thereby limiting the extent of mitophagy under
hypoxia [106]. In summary, it is clear that there are mul-
tiple redundant pathways modulating mitochondrial
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mains how these mechanisms are coordinately regulated
in response to different stresses and how they may be dis-
rupted in cancer.
Effects of autophagy inhibition versus mitophagy
inhibition on tumorigenesis
Several recent publications have highlighted the accumu-
lation of defective mitochondria as explaining the block to
tumor progression when macro-autophagy is inhibited
[107-110]. In most of these mouse tumor models, macro-
autophagy was inhibited genetically through targeted dele-
tion of either Atg5 or Atg7 in the context of K-Ras-driven
oncogenesis [107-109,111]. While loss of autophagy pro-
moted early growth of tumors, progression to late-stage
and invasive disease was blocked highlighting a dual role
for autophagy in cancer - tumor suppressive early, while
tumor-promoting later. Based on these studies, it was pro-
posed that Ras-driven tumors were ‘autophagy addicted’
[107] such that tumors expressing activated K-Ras de-
pend on autophagy to maintain metabolic sufficiency
under nutrient depletion, ischemia, or matrix detach-
ment and this is particularly important at later stages of
tumorigenesis [107-110].
In-depth analyses of autophagy-deficient tumors in
these mice revealed the presence of clearly dysfunctional
mitochondria that exhibited altered morphology, inef-
fective fatty acid oxidation, reduced carbon flux through
Krebs cycle, and lipid accumulation [107-110]. This in
turn was linked to increased glucose uptake and reduced
oxygen consumption under aerobic conditions, both key
features of the Warburg effect. Given these mitochon-
drial inefficiencies and the failure to progress to malig-
nancy, it was suggested that these autophagy-deficient
tumors were akin to oncocytomas [108], benign tumors
forming in key endocrine organs that possess large num-
bers of swollen and dysfunctional mitochondria for as
yet unexplained reasons [112].
What is not clear from these studies is the extent to
which other defects arising from defective autophagy
contribute to the altered tumor phenotype and failure of
autophagy-deficient tumors to progress to malignant
carcinoma. Critically, autophagy is required for amino acid
recycling from the lysosome that plays a critical part in
growth under conditions of nutrient deprivation, such as
in ischemic tumors [1,5,113]. This could clearly contribute
to the tumor phenotype in addition to the observed de-
fects in mitochondria. Additionally, autophagy plays a key
role in other processes that affect malignant progres-
sion, including elimination of unfolded proteins and re-
ducing ER stress [114], effects on recruitment of tumor-
associated immune cells and anti-tumor immunosurveil-
lance [111,114-116], and secretion of cytokines and MMPs
[117]. Thus, while there are clearly mitochondrial defectsin tumors arising in mice deficient for autophagy as a
whole, the overall tumor phenotype cannot currently be
attributed entirely to the accumulation of defective
mitochondria. This becomes particularly apparent when
the effects of mitophagy deficiency on tumorigenesis are
examined (Table 1). Loss of Parkin, as already men-
tioned, promotes the Warburg Effect, tumorigenesis in
the liver, and irradiation-induced lymphomagenesis [35,37]
while inhibition of BNIP3 or NIX promotes tumor pro-
gression [64,100]. Thus, based on currently available data,
it appears that inhibition of mitophagy promotes tumor
progression and does not phenocopy inhibition of autoph-
agy, which blocks tumor progression (Table 1).
Targeting mitophagy as an approach to adjuvant
chemotherapy?
The adverse tumor-promoting effects of chronic mito-
phagy inhibition arising from deletion or inactivation of
genes such as Parkin and BNip3, particularly induction
of the Warburg effect, argue against targeting mitophagy
as a therapeutic strategy. However, for advanced tumors
that have already undergone the switch to glycolytic
metabolism but remain dependent on mitochondria for
other metabolic functions, such as glutaminolysis, fatty
acid oxidation, and generation of critical Krebs cycle inter-
mediates, acute chemical inhibition of mitophagy remains
a valid approach to be tested therapeutically. Since tumor
cells already produce increased ROS compared to normal
cells [118], the combined effect of further increased ROS
and reduced mitochondrial metabolism arising from in-
hibition of mitophagy may be synergistic and promote
efficient tumor cell killing while sparing normal cells that
are less likely to have dysfunctional mitochondria and
therefore likely to be less sensitive to mitophagy inhibition
(Figure 3). Before such approaches can be adopted though,
it will be necessary to investigate further how much mito-
chondrial damage or dysfunction can be tolerated by nor-
mal versus tumor cells, and for how long, before loss of
viability. Once mitophagy is inhibited, for example, it is
not clear how rapidly damaged mitochondria accumulate
and to what extent this varies depending on cell type, the
specific type of mitochondrial damage sustained, the na-
ture of the damaging stress applied, or indeed the ability
of the cell to adapt to mitochondrial dysfunction in other
ways. For example, increased mitochondrial fusion may
allow some cell types to distribute damaged mitochondrial
content in such a way that cells can survive mitophagy in-
hibition. It will also be important to identify which
tumors retain the capacity to undergo functional mito-
phagy and have not undergone selection for mitophagy
inactivation through deletion of Parkin, or silencing of
BNIP3, for example.
To overcome some of these potential caveats, comple-
mentary approaches combining acute mitophagy
Table 1 Comparison of the tumor phenotypes associated with deregulation of key regulators of mitophagy and
general autophagy
Gene (human/mouse) Linked human cancer Mouse model phenotype Reference
Mitophagy regulators
Parkin Parkin located at chr. 6q25-q26 is significantly
deleted in bladder, lung, breast, and
ovarian cancer.




BNIP3/Bnip3 BNIP3 is up-regulated in DCIS; epigenetically
silenced in hematologic, liver, lung, colorectal,
and pancreas cancer.
Knockdown of BNIP3 promotes metastasis in an
orthotopic mouse model of breast cancer.
[86-91,100]
BNIP3L/Bnip3L (NIX/Nix) NIX is up-regulated in DCIS correlating
with hypoxia.




BECN1/Becn1 Mono-allelic deletion BECN1 in breast, ovarian,
and prostate cancer, although linkage to
BRCA1 calls significance of BECN1 deletion
into question.
Becn1 heterozygotes are predisposed to
lymphoma, hepatocellular carcinoma, and other
cancers; Becln1 deficiency promotes tumor
growth in xenografts.
[124-127]
p62/SQSTM1 p62/SQSTM1 amplification on chr.5q linked to
clear cell renal cell carcinoma. Over-expressed
in lung, breast and prostate cancer.
p62-null mice resistant to Ras-driven lung
tumorigenesis. Loss of p62 reduces liver
tumorigenesis in Atg7-deficient mice and
other models.
[128-130]
ATG5/Atg5 Not reported. Deletion of Atg5 promotes early-stage tumor
growth in K-Ras driven lung and pancreas
cancers but inhibits progression to malignancy.
[109,111]
ATG7/Atg7 Silenced in HNSCC. Deletion of Atg7 promotes early-stage tumor
growth in K-Ras and B-Raf-driven lung and
K-Ras-driven pancreas cancers but inhibits
progression to malignancy.
[108-110,131]
FIP200 (RB1CC1) Inactivating truncation mutations found in
human breast cancers leads to repression of
the RB tumor suppressor.
Loss of FIP200 inhibits primary tumor growth
and metastasis in the MMTV-PyVT mouse model
of mammary tumorigenesis in a p62-dependent
manner.
[116,132]
Figure 3 Strategies to target mitophagy for cancer therapy. Tumor cells are likely to be more dependent on functional mitophagy than
normal cells due the increased requirement to manage ROS levels, due to dependence on key aspects of mitochondrial metabolism, such as
glutaminolysis, particularly given the ischemic nature of advanced macroscopic tumors. Such a dependence on mitophagy could be exploited
therapeutically by the development of specific small molecule inhibitors of mitophagy that could be combined with other drugs that induce
mitochondrial dysfunction, such as respiratory inhibitors or antibiotics, to further increase the requirement for functional mitophagy.
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Warburg effect) might be more effective. Alternatively,
acute induction of mitochondrial dysfunction could be
used to unmask a dependence on mitophagy, as opposed
to relying on mitophagy inhibition on its own that will
only kill cells that have an inherently high normal rate of
mitochondrial turnover and/or high rate of mitochondrial
damage accumulation (Figure 3). Such acute stresses
could include inhibiting respiration with metformin or
other respiratory inhibitors. Interestingly, the increased
sensitivity of K-RasG12D; Lkb1 null lung tumors to phen-
formin (a more potent analog of metformin) was
partially attributed to mitophagy defects in the absence
of AMPK/ULK1 signaling downstream of Lkb1 [119].
Moreover, an RNAi screen to identify genes that sensi-
tized tumor cells to low glucose found that inhibition of
components of the electron transport chain was most
effective in limiting the growth of patient-derived tumor
cells [120]. This implicates mitochondrial oxidative phos-
phorylation taking place at the mitochondria as the key
determinant of sensitivity to low glucose, providing fur-
ther rationale for the use of biguanides, such as metfor-
min, in cancer therapy [120]. Along similar lines, another
recent study identified VLX600 as a drug that inhibits
mitochondrial respiration, induces mitochondrial dysfunc-
tion, and preferentially kills tumor cells when exposed to
nutrient stress [121]. In addition, the resistance of dor-
mant tumor cells in K-Ras-driven pancreatic cancer to
oncogene ablation was shown to be dependent on func-
tional OXPHOS [122]. More speculatively, antibiotics
such as tetracycline could be re-purposed for cancer
therapy in combination with mitophagy inhibitors. These
mito-toxic antibiotics inhibit mitochondrial protein trans-
lation, similar to their action in bacteria, resulting in a
‘mitonuclear’ protein imbalance that activates the mito-
chondrial unfolded protein response (UPRmt) that is
commonly resolved by mitophagy [50,123]. Treatment of
tumor cells with any one of these drugs would be pre-
dicted to elicit an acute dependence on mitophagy for
survival before other adaptive survival mechanisms come
into play. Thus, combining one or more of these drugs
with a drug that inhibits mitophagy may provide added
benefit in terms of treating cancers.
Conclusions
Mitophagy is a clearly distinct form of autophagy involv-
ing the selective degradation of mitochondria at the
autophagolysosome. Specific defects in mitophagy have
been linked to human cancers through deletion of key
regulators such as Parkin and BNIP3. Additionally, mouse
models reveal distinct phenotypes when mitophagy is spe-
cifically inhibited compared to that observed when general
autophagy is inhibited. Targeting mitophagy may there-
fore offer opportunities to more selectively inhibittumor progression to malignancy where one may take
advantage of the acute sensitivity of tumor cells to mito-
chondrial dysfunction when combined with other drugs
or stresses.
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